on 25th, during Rising Israeli Stars Session (from 15.40 to 16.15}
Company Profile
Home / Ambulatory monitoring platform that can easily and precisely monitor the lung function, alert the medical provider on deterioration and allow change of treatment at home before Asthma exacerbation.
Non invasive accurate monitoring of breathing
Recognition of pathologic breathing patterns
Breakthrough in Respiratory Care
• Novel respiratory disease management technology
• Enables non invasive accurate monitoring of breathing
• Precise recognition of pathologic breathing patterns
• The 4 P’s: Predictive, Personalized, Preemptive, Participatory
Mr. Lior Teitelbaum, VP Business Development at MindUP is a healthcare executive with extensive experience in Business Development, Strategy, Scouting and Licensing, Partnering, Portfolio Planning and Strategy and Strategic Alliance Management in the Medical Technology, Pharmaceutical and Biotechnology industries. Prior to joining MindUP Lior was Senior Director of Business Development at BioLineRx LTD, a biopharmaceutical development company, prior to that he served as Director of Business Development at MetaCure, a medical device company focusing on treatment of type 2 diabetes, Prior to that he served as Deal flow and Business Development Manager at Elron Electronic Industries, a technology focused investment company. Lior holds an MBA from the Recanati School of management at Tel Aviv University and an MSc. in molecular genetics from the Weizmann Institute of Science.
RetiCare IVS
Presentation Time and Location
on 27th, during Rising Biotech Stars Session (from 14.00 to 16.00)
RetiCare IVS – Setting the sight on new treatments for retinal diseases
RetiCare is a Danish biotech start-up company focusing on developing new neuroprotective treatments for eye disorders. The company has established in-house a highly translational animal model with end-points that are similar to the diagnostic tool applied in human clinical ophthalmology.
The primary focus is on continuing the development of a new peptide treatment with a novel target discovered and characterized by RetiCare’s founders, which induces neuroprotective effects in the retina. The translational setup will also be used to insource and screen new projects with other targets.
Based on existing data and clinical development feasibility the selected initial indication is retinal detachment, but the indication can upon proof-of concept be expanded to include other indications with involvement death of retinal cells such as glaucoma, age-related macula degeneration, diabetic macular edema, and others.
The team behind RetiCare has in combination several decades of experiences within ophthalmological diseases, neuroprotective effects, clinical practice, and life-science entrepreneurship.
RetinAI Medical is a Swiss company that supports eye care professionals and patients throughout the medical examination process using Artificial Intelligence (AI). Our vision is to foster the transition from reactive medicine to preventive medicine for high-impact diseases such as Age-related Macular Degeneration (AMD), Diabetic Retinopathy (DR) and Glaucoma.
Our solutions rely on the latest advances in medical image analysis, ophthalmology and machine learning. We have a unique team of scientists working to fully realize the capabilities of AI, and to integrate this technology into the next generation of medical devices.
CEO and Co-Founder of RetinAI and PhD in machine learning and medical imaging in ophthalmology.
RiboStruct
Presentation Time and Location
on 27th, during Rising Biotech Stars Session (from 14.00 to 16.00)
Company Profile
RiboStruct is developing the first generic treatment for genetic diseases.
RiboStruct leverages the long-term work of Marat Yusupov and Gulnara Yusupova on the crystallographic study of the eukaryotic ribosome to develop new drugs, in particular "readthrough compounds" targeting the human ribosome for the treatment of monogenic genetic diseases when they are caused by nonsense mutations (10-15% of cases). Distinctively from gene therapies, where a specific program is needed for each disease, RiboStruct develops a pharmacological "protein repair therapy" approach, with the goal to cure multiple diseases with the same molecule by acting on a common mechanism. More than 7000 genetic diseases have been described so far, affecting altogether 300 million people worlwide.
Aminoglycosides are known to help the ribosome overcome premature stop codons to restore the synthesis of full-length proteins but their high toxicity prevents their use on the long term as needed for the treatment of monogenic diseases caused by nonsense mutations.
RiboStruct is developing non-aminoglycoside readthrough compounds using a fragment- and structure-based drug design approach relying on an exclusive know-how on the crystallographic structure determination of the whole eukaryotic ribosome in complex with ligands and on the strong biophysical capabilities of its strategic partner NovAliX (http://www.novalix-pharma.com/).
Jean-Paul Renaud created RiboStruct as a spinoff company from IGBMC (Illkirch, France) end of 2015.
He was previously cofounder and CSO Science & Technology at NovAliX (2010-2014), creator and President & CEO-CSO at AliX (2002-2008), and CNRS Research Director at IGBMC (2000-2002).
Jean-Paul holds an Engineering Diploma from ENSCP (1982) and a PhD in Organic Chemistry from UPMC (1986).
Awards :
2017 Laureate, 19th French National Innovative Startup Competition (i-LAB 2017) (for RiboStruct) 2006 Laureate, Réseau Entreprendre Alsace (for AliX) 2002 Laureate, 4th French National Innovative Startup Competition (i-LAB 2002) (for AliX) 1986 Eugène Schueller Prize
Responsive Web Design powered by 